Fibrinogen in Liver Transplant Subjects (FITS)
The study is a prospective, multi-centered, unblinded, randomized controlled pilot study. The primary objective is to compare functional hemostatic capacity of two approved products Intercept Fibrinogen Complex (IFC) to Standard Cryoprecipitate Antihemophilic Factor (AHF) for liver transplant patients with bleeding and hypofibrinogenemia to determine impact of earlier access to a concentrated source of fibrinogen in a goal-directed manner.
• 18 years of age or older
• Scheduled to undergo cadaveric liver transplant
• Meets at least one of the following criteria: Baseline fibrinogen \<200 mg/dL or clinically significant visoelastic testing
• Meets any one of the following criteria: Alcoholic cirrhosis, Metabolic dysfunction associated steatohepatitis (MASH) (previously known as Nonalcoholic Steatohepatitis (NASH)), HCV infection